-transparent.png){kind=logo}
1. The effects of intravenous bolus doses of human calcitonin-gene-related peptide (hCGRP) were studied in ten healthy male volunteers. 2.5, 10 and 25 micrograms of hCGRP and placebo were administered to each subject in a randomized double-blind study. 2. hCGRP had no effect on systolic or diastolic blood pressure in the supine or standing position. 3. hCGRP increased supine and standing heart rate. Both the extent and duration of the tachycardia were dose related. 4. Plasma noradrenaline levels were transiently increased after 10 and 25 micrograms of hCGRP. 5. All subjects displayed marked facial flushing after the two higher doses of hCGRP. 6. We conclude that systemic administration of hCGRP produces tachycardia and stimulation of the sympathetic nervous system in the absence of any change in blood pressure.
C W Howden, and
C Logue, and
K Gavin, and
L Collie, and
P C Rubin
December 1989,
British journal of pharmacology,
C W Howden, and
C Logue, and
K Gavin, and
L Collie, and
P C Rubin
June 1991,
Angiology,
C W Howden, and
C Logue, and
K Gavin, and
L Collie, and
P C Rubin
April 1986,
Clinical science (London, England : 1979),
C W Howden, and
C Logue, and
K Gavin, and
L Collie, and
P C Rubin
June 1991,
British journal of pharmacology,
C W Howden, and
C Logue, and
K Gavin, and
L Collie, and
P C Rubin
January 1991,
Peptides,
C W Howden, and
C Logue, and
K Gavin, and
L Collie, and
P C Rubin
June 1991,
Journal of neuroendocrinology,
C W Howden, and
C Logue, and
K Gavin, and
L Collie, and
P C Rubin
February 1988,
Gut,
C W Howden, and
C Logue, and
K Gavin, and
L Collie, and
P C Rubin
July 1990,
Journal of the autonomic nervous system,
C W Howden, and
C Logue, and
K Gavin, and
L Collie, and
P C Rubin
January 1984,
Psychopharmacology bulletin,
C W Howden, and
C Logue, and
K Gavin, and
L Collie, and
P C Rubin
May 1990,
Molecular and cellular endocrinology,
